A Biotech Company Had $268 Million in Cash. After a Failed Drug Trial, It Announced a 46 Percent Workforce Cut
The biotech company is downsizing to fund another trial after a drug showed no meaningful benefit. The move comes just a year after its IPO.
⬅ Back home Read full article ➡